Application of breast cancer risk prediction models in clinical practice

Journal of Clinical Oncology

Volumn 21, Issue 4, 2003, Pages 593-601

  Domchek, Susan M ^a   Eisen, Andrea ^a   Calzone, Kathleen ^a   Stopfer, Jill ^a   Blackwood, Anne ^a   Weber, Barbara L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; RALOXIFENE; TAMOXIFEN; ANTIESTROGEN;

ACCURACY; ARTICLE; BREAST CANCER; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HEALTH CARE MANAGEMENT; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; WOMEN'S HEALTH; BIOLOGICAL MODEL; BREAST TUMOR; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; MUTATION; PREDICTION AND FORECASTING; REVIEW; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; RALOXIFENE; RISK ASSESSMENT; TAMOXIFEN;

EID: 0037441790     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.07.007     Document Type: Article

References (80)

1. Martin AM, Weber BL: Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst 92:1126-1135, 2000
2. Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622, 2002
3. Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615, 2002
4. Rebbeck TR, Levin AM, Eisen A, et al: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91:1475-1479, 1999
5. Narod SA, Brunet JS, Ghadirian P, et al: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356:1876-1881, 2000
6. Narod SA, Risch H, Moslehi R, et al: Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339:424-428, 1998
7. Walker GR, Schlesselman JJ, Ness RB: Family history of cancer, oral contraceptive use, and ovarian cancer risk. Am J Obstet Gynecol 186:8-14, 2002
8. Hartmann LC, Schaid DJ, Woods JE, et al: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77-84, 1999
9. Hartmann LC, Sellers TA, Schaid DJ, et al: Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93:1633-1637, 2001
10. Meijers-Heijboer H, van Geel B, van Putten WL, et al: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159-164, 2001
11. Scheuer L, Kauff N, Robson M, et al: Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20:1260-1268, 2002
12. Brekelmans CT, Seynaeve C, Bartels CC, et al: Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 19:924-930, 2001
13. DeMichele A, Weber BL: Risk management in BRCA1 and BRCA2 mutation carriers: Lessons learned, challenges posed. J Clin Oncol 20:1164-1166, 2002
14. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
15. Smith RA, Cokkinides V, von Eschenbach AC, et al: American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 52:8-22, 2002
16. Claus EB, Risch N, Thompson WD: Autosomal dominant inheritance of early-onset breast cancer: Implications for risk prediction. Cancer 73:643-651, 1994
17. Gail MH, Brinton LA, Byar DP, et al: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879-1886, 1989
18. Couch FJ, DeShano ML, Blackwood MA, et al: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336:1409-1415, 1997
19. Shattuck-Eidens D, Oliphant A, McClure M, et al: BRCA1 sequence analysis in women at high risk for susceptibility mutations: Risk factor analysis and implications for genetic testing. J Am Med Assoc 278:1242-1250, 1997
20. Frank TS, Manley SA, Olopade OI, et al: Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16:2417-2425, 1998
21. Parmigiani G, Berry D, Aguilar O: Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145-158, 1998
22. Chang-Claude J, Dong J, Schmidt S, et al: Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes. J Med Genet 35:116-121, 1998
23. Hartge P, Struewing JP, Wacholder S, et al: The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64:963-970, 1999
24. Vahteristo P, Eerola H, Tamminen A, et al: A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 84:704-708, 2001
25. Gilpin CA, Carson N, Hunter AG: A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clin Genet 58:299-308, 2000
26. Krainer M, Silva-Arrieta S, FitzGerald MG, et al: Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 336:1416-1421, 1997
27. Ithier G, Girard M, Stoppa-Lyonnet D: Breast cancer and BRCA1 mutations. N Engl J Med 334:1198-1199, 1996
28. FitzGerald MG, MacDonald DJ, Krainer M, et al: Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 334:143-149, 1996
29. Malone KE, Daling JR, Neal C, et al: Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 88:1393-1402, 2000
30. Blackwood MA, Yang H, Margolin A, et al: Predicted probability of breast cancer susceptibility gene mutations. Breast Cancer Res Treat 69:223, 2001
31. Peto J, Collins N, Barfoot R, et al: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943-949, 1999
32. Frank TS, Deffenbaugh AM, Reid JE, et al: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol 20:1480-1490, 2002
33. Berry DA, Parmigiani G, Sanchez J, et al: Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 89:227-238, 1997
34. Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56:265-271, 1995
35. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689, 1998
36. Fodor FH, Weston A, Bleiweiss IJ, et al: Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 63:45-51, 1998
37. Berry DA, Iversen ES, Jr, Gudbjartsson DF, et al: BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20:2701-2712, 2002
38. Abeliovich D, Kaduri L, Lerer I, et al: The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60:505-514, 1997
39. Levy-Lahad E, Catane R, Eisenberg S, et al: Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: Frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 60:1059-1067, 1997
40. Beller U, Halle D, Catane R, et al: High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history. Gynecol Oncol 67:123-126, 1997
41. Gotlieb WH, Friedman E, Bar-Sade RB, et al: Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. J Natl Cancer Inst 90:995-1000, 1998
42. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 349:1505-1510, 1997
43. Rosen PP, Kosloff C, Lieberman PH, et al: Lobular carcinoma in situ of the breast: Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol 2:225-251, 1978
44. Haagensen CD, Lane N, Lattes R, et al: Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 42:737-769, 1978
45. Dupont WD, Page DL: Risk factors for breast cancer in women with proliferate breast disease. N Engl J Med 312:146-151, 1985
46. London SJ, Connolly JL, Schnitt SJ, et al: A prospective study of benign breast disease and the risk of breast cancer. JAMA 267:941-944, 1992
47. Brose MS, Rebbeck TR, Calzone KA, et al: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365-1372, 2002
48. Thompson D, Easton DF: Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358-1365, 2002
49. Shih HA, Nathanson KL, Seal S, et al: BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Clin Cancer Res 6:4259-4264, 2000
50. The Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310-1316, 1999
51. Murphy KM, Brune KA, Griffin C, et al: Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: Deleterious BRCA2 mutations in 17%. Cancer Res 62:3789-3793, 2002
52. Couch FJ, Farid LM, DeShano ML, et al: BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 13:123-125, 1996
53. Friedman LS, Gayther SA, Kurosaki T, et al: Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 60:313-319, 1997
54. Gerrero MR, Brose M, Couch FJ, et al: BRCA1 and BRCA2 germline mutations in male breast cancer cases. J Clin Oncol 20:413a, 2001 (abstr 1650)
55. Tang NL, Pang CP, Yeo W, et al: Prevalence of mutations in the BRCA1 gene among Chinese patients with breast cancer. J Natl Cancer Inst 91:882-885, 1999
56. Tang NL, Choy KW, Pang CP, et al: Prevalence of breast cancer predisposition gene mutations in Chinese women and guidelines for genetic testing. Clin Chim Acta 313:179-185, 2001
57. Sng JH, Chang J, Feroze F, et al: The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives. Br J Cancer 82:538-542, 2000
58. Panguluri RC, Brody LC, Modali R, et al: BRCA1 mutations in African Americans. Hum Genet 105:28-31, 1999
59. Gao Q, Tomlinson G, Das S, et al: Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet 107:186-191, 2000
60. Gao Q, Adebamowo CA, Fackenthal J, et al: Protein truncating BRCA1 and BRCA2 mutations in African women with pre-menopausal breast cancer. Hum Genet 107:192-194, 2000
61. Petrij-Bosch A, Peelen T, van Vliet M, et al: BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 17:341-345, 1997
62. The BRCA1 Exon 13 Duplication Screening Group: The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. Am J Hum Genet 67:207-212, 2000
63. Ottman R, Pike MC, King MC, et al: Practical guide for estimating risk for familial breast cancer. Lancet 2:556-558, 1983
64. Anderson DE, Badzioch MD: Risk of familial breast cancer. Cancer 56:383-387, 1985
65. Houlston RS, McCarter E, Parbhoo S, et al: Family history and risk of breast cancer. J Med Genet 29:154-157, 1992
66. Sattin RW, Rubin GL, Webster LA, et al: Family history and the risk of breast cancer. JAMA 253:1908-1913, 1985
67. Offit K, Brown K: Quantitating familial cancer risk: A resource for clinical oncologists. J Clin Oncol 12:1724-1736, 1994
68. Claus EB, Risch N, Thompson WD: Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 48:232-242, 1991
69. Claus EB, Risch N, Thompson WD: The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat 28:115-120, 1993
70. McGuigan KA, Ganz PA, Breant C: Agreement between breast cancer risk estimation methods. J Natl Cancer Inst 88:1315-1317, 1996
71. McTiernan A, Kuniyuki A, Yasui Y, et al: Comparisons of two breast cancer risk estimates in women with a family history of breast cancer. Cancer Epidemiol Biomarkers Prev 10:333-338, 2001
72. Ford D, Easton DF, Peto J: Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:1457-1462, 1995
73. Struewing JP, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408, 1997
74. Oddoux C, Struewing JP, Clayton CM, et al: The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14:188-190, 1996
75. Struewing JP, Tarone RE, Brody LC, et al: BRCA1 mutations in young women with breast cancer. Lancet 347:1493, 1996
76. Roa BB, Boyd AA, Volcik K, et al: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14:185-187, 1996
77. Newman B, Mu H, Butler LM, et al: Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279:915-921, 1998
78. Rubin SC, Blackwood MA, Bandera C, et al: BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: Relationship to family history and implications for genetic testing. Am J Obstet Gynecol 178:670-677, 1998
79. Stratton JF, Gayther SA, Russell P, et al: Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 336:1125-1130, 1997
80. Rockhill B, Spiegelman D, Byrne C, et al: Validation of the Gail, et al model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93:358-366, 2001